In the MC38-CEA colon carcinoma model, we observed a significant reduction in tumor volumes in the cohort treated with αTIGIT + bintrafusp alfa in comparison to untreated animals, or cohorts that receive either molecule as monotherapy (Figure 2b), as well as an increase in median survival (Figure 2c). Here, CEACAM5 is linked to colon carcinoma.